Longitudinal pneumococcal surveillance is important in monitorization of vaccine coverage and ef-fectiveness and guidance for future vaccination programmes.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:The introduction of conjugated pneumococcal vaccines into routine vaccination schedules resulted in a reduction in invasive pneumococcal disease due to vaccine strains.
📊
Key Findings & Data:However, invasive pneumococcal diseas-es caused by non-vaccine strains have increased.
💡
Conclusion & Impact:Longitudinal pneumococcal surveillance is important in monitorization of vaccine coverage and ef-fectiveness and guidance for future vaccination programmes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
The introduction of conjugated pneumococcal vaccines into routine vaccination schedules resulted in a reduction in invasive pneumococcal disease due to vaccine strains. However, invasive pneumococcal diseas-es caused by non-vaccine strains have increased. Here, we present a fully vaccinated child with 13-valent pneumococcal conjugate vaccine, who suffered from meningitis caused by Streptococcus pneumoniae serotype 24A, a non-vaccine and very rare serotype. Longitudinal pneumococcal surveillance is important in monitorization of vaccine coverage and ef-fectiveness and guidance for future vaccination programmes.
🔖
Cite This Article
AKTÜRK, H., AKOĞLU, H. A., KÜLCÜ, N. U., YILDIZ, F. M., ÖKSÜZ, L., GÜRLER, N., YALÇIN, E. U., HACIFAZLIOĞLU, N. E. (2019). Meningitis Due to Streptococcus pneumoniae Serotype 24A in a Child Vaccinated with 13-valent Pneumococcal Conjugate Vaccine. Çocuk Enfeksiyon Dergisi, Cilt: 13 - Sayı: 1, e39–e41. https://ajindex.com/articles/348687
Imöhl M, Möller J, Reinert RR, Perniciaro S, van der Linden M, Aktas O. Pneumococcal meningitis and vaccine effects inthe era of conjuga-te vaccination: results of 20 years of nationwide surveillance in Germany. BMC Infect Dis 2015;15:61
Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33:2759-62
Ceyhan M, Ozsurekci Y, Gürler N, Öksüz L, Aydemir S, Ozkan S, et al. Se-rotype distribution of Streptococcus pneumoniae in children with invasi-ve diseases in Turkey: 2008-2014. Hum Vaccin Immunother 2016;12:308-13
Gant CM, Rosingh AW, López-Hontangas JL, van der Heijden M, Gonzá-lez-Morán F, Bijlsma JJ, Canton E; RedMiva (Network of Microbiological Vigilance of Comunidad Valenciana).Serotype distribution and antimic-robial resistance of invasive pneumococcal disease strains in the Comu-nidad Valenciana, Spain, during the winter of 2009-2010: low PCV7 co-verage and high levofloxacin resistance. Antimicrob Agents Chemother 2012;56:4988-9
Ramdani-Bouguessa N, Ziane H, Bekhoucha S, Guechi Z, Azzam A, Touati D, et al. Evolution of antimicrobial resistance and seroty-pe distribution of Streptococcus pneumoniae isolated from child-ren with invasive and noninvasive pneumococcal diseases in Alge-ria from 2005 to 2012. New Microbes New Infect 2015;6:42-8
Pantosti A, Gherardi G, Conte M, Faella F, Dicuonzo G, Beall B. A no-vel, multiple drugresistant, serotype 24F strain of Streptococcus pneu-moniae that caused meningitisin patients in Naples, Italy. Clin Infect Dis 2002;35:205-8
Kalin M. Pneumococcal serotypes an their clinical relevance. Tho-rax 1998;53:159-62
Levy C, Varon E, Picard C, Béchet S, Martinot A, Bonacorsi S, et al. Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugatevaccine in France. Pediatr Infect Dis J 2014;33:1216-21
Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Ef-fect of the 13-valent pneumococcal conjugate vaccine on invasive pneu-mococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015;15:535-43
Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-a-cquired pneumonia in children. Clin Infect Dis 2014;58:918-24.